PT-141 (Bremelanotide) | Research Peptide
AUD $120
For laboratory research use only. Not for human use.
Research-grade PT-141 (Bremelanotide) — a melanocortin receptor agonist studied in preclinical and clinical research for sexual health and arousal pathways. Third-party HPLC tested to ≥98% purity. For laboratory research use only.
Supply Specifications
| Peptide | PT-141 (Bremelanotide) |
| Mechanism | Melanocortin receptor agonist (MC1R, MC3R, MC4R) |
| Format | Lyophilised powder |
| Purity | ≥98% by HPLC |
| Testing | Third-party HPLC + Mass Spec |
| Storage | -20°C lyophilised |
| Use | Laboratory research use only |
| Price | AUD $120 |
Research Summary
PT-141 (Bremelanotide) is a cyclic heptapeptide that acts as a non-selective agonist at melanocortin receptors (MC1R, MC3R, MC4R). It was originally developed as a tanning agent but research pivoted to its apparent effects on sexual arousal pathways.
PT-141 received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the few research peptides to achieve regulatory approval. It is not TGA-approved in Australia and is available for laboratory research use only.
Related Research
Disclaimer: All products supplied by PeptideIQ are for laboratory research use only. They are not approved for human use, consumption, or therapeutic application. PeptideIQ complies with all applicable Australian regulations including the Therapeutic Goods Act 1989.